KEYNOTE-045: 5-Yr Follow-up of Pembrolizumab in Recurrent Advanced Urothelial Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
With a median follow-up of 5 years, pembrolizumab continued to show improved overall survival compared with investigator’s choice of chemotherapy in patients with recurrent advanced urothelial cancer on the KEYNOTE-045 trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 467 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

From Clinical Care Options (CCO), an expert video webinar on immunotherapy and targeted agents in RCC treatment

Elizabeth R. Plimack, MD, MS
Program Director
Rana R. McKay, MD Brian Rini, MD, FASCO
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 18, 2021 Expired: November 17, 2022

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

From Clinical Care Options (CCO), experts discuss advances in prostate cancer treatment, including use of GnRH antagonists and androgen receptor inhibitors.

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD, MPH Released: November 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue